What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from the OlympiA study demonstrates a clear clinical advantage for olaparib, showing significant improvements in invasive disease-free survival, distant disease-free survival, and overall survival compared to placebo. The primary outcome of invasive disease-free survival showed a statistically significant difference of 7.3% at 4 years, indicating a strong therapeutic impact.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for olaparib are within NICE’s acceptable range for Healthcare resources, particularly after the company revised its commercial arrangement. The ICERs were reported to be substantially below £30,000 per QALY gained, indicating a strong economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that olaparib has a positive impact on HRQoL, with patient experts reporting manageable side effects and the ability to maintain daily activities. However, the utility values derived from the company’s analysis were questioned for being unrealistically high, which slightly limits the strength of the HRQoL evidence.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Olaparib is reported to have a very good safety profile, with manageable adverse events. Patient feedback indicated that side effects were tolerable, which supports the conclusion of a favorable safety profile compared to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The committee noted that olaparib was compared against appropriate standard care options, including routine monitoring for cancer recurrence. This selection aligns well with current treatment pathways, providing a relevant context for the evaluation.
Is the population defined the way payers need it? — Patient Population and Subgroups
The OlympiA trial included a diverse patient population with BRCA mutation-positive HER2-negative high-risk early breast cancer, and the criteria for defining high risk were deemed appropriate. The trial’s demographics reflect the intended real-world population, enhancing generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Olaparib can be integrated into existing treatment pathways with minor adjustments, as it is used after neoadjuvant or adjuvant chemotherapy. The oral administration and infrequent monitoring requirements facilitate its adoption into clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of olaparib are manageable, with the potential for cost savings due to its effectiveness in preventing cancer recurrence. The economic model supports a favorable budget impact, aligning with Healthcare resource planning.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust Phase III RCT (OlympiA) with a large sample size (n=1,836) and low risk of bias. However, some extrapolations and assumptions in the economic model introduce minor concerns regarding robustness.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties related to long-term outcomes and extrapolations in the economic model, the overall context of unmet need and the positive societal impact of olaparib mitigate these concerns, leading to a favorable assessment.
